Premature Infant: Treating Underdeveloped Lungs

Skip to the navigation

Topic Overview

Particularly when an infant is born before 36 weeks' gestation, the lungs are immature, and the body has limited muscle strength and energy for breathing. So the premature infant may not get enough oxygen. This can cause serious health problems. It is common at birth for a premature infant to need oxygen therapy, a ventilator, and/or medicine. These can help the baby absorb oxygen and breathe.

Infants whose lungs have been quickly matured with corticosteroid treatment before birth have a lot fewer problems than those who are not treated. With this treatment, the mother gets a series of shots of corticosteroids before she gives birth.

Infants with underdeveloped lungs often lack surfactant. This is a substance that coats the airways and prevents them from collapsing and sticking together. When premature lungs are treated with surfactant after birth, the infant's blood oxygen levels usually improve within minutes. Surfactant treatment reduces the risk and the severity of respiratory distress syndrome (RDS) in premature infants. It also reduces the overall risk of death.footnote 1 Surfactant also helps treat RDS.

Unlike corticosteroid treatment before birth, giving corticosteroids to a baby after birth is losing favor among experts. Current research is looking at how this medicine can be safely used to improve lung function without causing other problems. (It can cause neurological problems, gastrointestinal bleeding and damage, blood sugar problems, and high blood pressure.)

Related Information

References

Citations

  1. Cunningham FG, et al. (2010). Diseases and injuries of the fetus and newborn. In Williams Obstetrics, 23rd ed., pp. 605-643. New York: McGraw-Hill.

Other Works Consulted

  • Engle WA, Committee on Fetus and Newborn (2008). Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics, 121(2): 419-432.
  • Soll R, Özek E (2010). Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews (1).

Credits

ByHealthwise Staff

Primary Medical ReviewerSarah Marshall, MD - Family Medicine

Kathleen Romito, MD - Family Medicine

John Pope, MD - Pediatrics

Specialist Medical ReviewerJennifer Merchant, MD - Neonatal-Perinatal Medicine

Current as ofMay 4, 2017